Abstract 141P
Background
Immunotherapy based on Immune Checkpoint Inhibitors (ICI) has changed the management of advanced Non-Small Cell Lung Cancer (NSCLC), achieving long-time responders for the first time. However, response rates remain below 40%. A deeper understanding of ICI response mechanisms and the identification of predictive biomarkers is still an urgent need. A close relation between DNA methylation and the immunogenic status of the tumor microenvironment (TME) has been recently proposed for several solid tumors. In this work we evaluated the epigenetic and transcriptomic status of NSCLC tumors before immunotherapy to disclose the possible role of DNA methylation in ICI response, and to identify immune-related signatures that predict ICI outcome.
Methods
We included 24 advanced NSCLC patients treated with anti-PD1 at first line. DNA and RNA were extracted from FFPE tumor biopsies. Genome-wide DNA methylation was quantified with the MethylationEPIC array and RNA-seq was performed with a NovaSeq6000 system. Data was annotated to the GRCh38 genome and bioinformatics was performed with R/Bioconductor.
Results
Differential methylation and expression patterns were found between patients with radiological response (n=10) and non-responder patients (n=14). We identified a DNA methylation signature that predicts a 6-months response to anti-PD1 therapy. Also, we reported a methylation profile associated with longer progression-free survival (PFS). Functional consequences of differential DNA methylation were confirmed by RNA-seq, identifying dysregulated immune pathways significantly enriched for both methylation and transcriptomic signatures. Pathways associated to ICI response related to T-cell and toll-like receptors signaling pathways, MHC-II complex, and interleukins. We also found aberrant methylation of the PI3K-Akt signaling pathway, which plays an essential role in the TME, regulating immune checkpoints and the sensitivity to ICI.
Conclusions
Overall, our results confirm that DNA methylation plays a role in the response to ICI in advanced NSCLC. These immune-related methylation profiles can predict response to anti-PD1 therapy and correlate with longer PFS, representing a source of predictive biomarkers for ICI outcome.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This research project is funded by the national Institute of Health Carlos III (ISCIII, PI21/00348). M.M-F. is supported by the Miguel Servet program (CP20/00188) from the ISCIII and the European Social Fund (“Investing in your future”).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract